Literature DB >> 22707196

C-X-C chemokine receptor type 5 gene polymorphisms are associated with non-Hodgkin lymphoma.

Haihan Song1, Danian Tong, Zhanshan Cha, Jianwen Bai.   

Abstract

The C-X-C chemokine receptor type 5 (CXCR5) is one of the principal regulators for targeting T cells, B cells and dendritic cells into secondary lymphoid organs. Polymorphism studies of CXCR5 gene remain extremely scarce. The aim of this study was to examine the effect of polymorphisms in the CXCR5 gene on the development of non-Hodgkin lymphoma (NHL) in the Chinese population. Four polymorphisms in CXCR5 gene, rs148351692C/G, rs6421571C/T, rs80202369G/A and rs78440425G/A, were tested by polymerase chain reaction-restriction fragment length polymorphism in 404 NHL cases and 456 age-matched healthy controls. Data were analyzed using the χ(2) test. Results showed that individuals with the rs6421571 CT, rs6421571 TT and rs80202369 AA genotype had significantly increased susceptibility to NHL [Odd ratio (OR) = 1.41, 95 % confidence interval (CI): 1.04-1.92, p = 0.028; OR = 2.30, 95 % CI: 1.44-3.65, p < 0.001; and OR = 3.24, 95 % CI: 1.26-8.32, p = 0.010, respectively]. When analyzing the haplotypes of these polymorphisms, the prevalence of the TGG (rs6421571, rs80202369, and rs78440425) haplotype was significantly higher in NHL cases than in controls (OR = 1.59, 95 % CI: 1.25-2.03, p < 0.001). In addition, numbers of rs6421571 TT genotype and T allele were significantly increased in NHL patients with high Ann Arbor stages (p < 0.03) or NHL with B cell subtype (p < 0.02). These data indicate that CXCR5 gene polymorphisms may be new risk factors for NHL. The finding that the adjacent SNPs, rs6421571C/T and rs80202369G/A, are both associated with NHL suggests that the 87 bp region carrying these 2 polymorphisms may have important functional significance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22707196     DOI: 10.1007/s11033-012-1717-6

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  21 in total

Review 1.  The role of chemokine receptors in primary, effector, and memory immune responses.

Authors:  F Sallusto; C R Mackay; A Lanzavecchia
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  B cells control the migration of a subset of dendritic cells into B cell follicles via CXC chemokine ligand 13 in a lymphotoxin-dependent fashion.

Authors:  Ping Yu; Yang Wang; Robert K Chin; Luisa Martinez-Pomares; Siamon Gordon; Marie H Kosco-Vibois; Jason Cyster; Yang-Xin Fu
Journal:  J Immunol       Date:  2002-05-15       Impact factor: 5.422

Review 3.  Chemokines and chemokine receptors in leukocyte trafficking.

Authors:  Timothy S Olson; Klaus Ley
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2002-07       Impact factor: 3.619

Review 4.  Systemic immunoregulatory and pathogenic functions of homeostatic chemokine receptors.

Authors:  Gerd Müller; Uta E Höpken; Harald Stein; Martin Lipp
Journal:  J Leukoc Biol       Date:  2002-07       Impact factor: 4.962

5.  A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1.

Authors:  M D Gunn; V N Ngo; K M Ansel; E H Ekland; J G Cyster; L T Williams
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

6.  CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma.

Authors:  Francesco Bertolini; Chiara Dell'Agnola; Patrizia Mancuso; Cristina Rabascio; Alessandra Burlini; Silvia Monestiroli; Alberto Gobbi; Giancarlo Pruneri; Giovanni Martinelli
Journal:  Cancer Res       Date:  2002-06-01       Impact factor: 12.701

7.  Secondary lymphoid-tissue chemokine is a functional ligand for the CC chemokine receptor CCR7.

Authors:  R Yoshida; M Nagira; M Kitaura; N Imagawa; T Imai; O Yoshie
Journal:  J Biol Chem       Date:  1998-03-20       Impact factor: 5.157

Review 8.  Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology.

Authors:  Antonia M S Müller; Gabriele Ihorst; Roland Mertelsmann; Monika Engelhardt
Journal:  Ann Hematol       Date:  2004-10-09       Impact factor: 3.673

9.  Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas.

Authors:  Livio Trentin; Anna Cabrelle; Monica Facco; Davide Carollo; Marta Miorin; Alicia Tosoni; Paola Pizzo; Gianni Binotto; Linda Nicolardi; Renato Zambello; Fausto Adami; Carlo Agostini; Gianpietro Semenzato
Journal:  Blood       Date:  2004-03-04       Impact factor: 22.113

10.  B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5.

Authors:  D F Legler; M Loetscher; R S Roos; I Clark-Lewis; M Baggiolini; B Moser
Journal:  J Exp Med       Date:  1998-02-16       Impact factor: 14.307

View more
  9 in total

1.  Epigenetic regulation of miR-518a-5p-CCR6 feedback loop promotes both proliferation and invasion in diffuse large B cell lymphoma.

Authors:  Qian Huang; Feng Zhang; Haiying Fu; Jianzhen Shen
Journal:  Epigenetics       Date:  2020-06-30       Impact factor: 4.528

2.  Lymphomas complicating primary Sjögren's syndrome: from autoimmunity to lymphoma.

Authors:  Gaetane Nocturne; Elena Pontarini; Michele Bombardieri; Xavier Mariette
Journal:  Rheumatology (Oxford)       Date:  2019-03-05       Impact factor: 7.580

3.  Polymorphism in interleukin 21 gene is associated with decreased susceptibility to diffuse large B cell lymphoma.

Authors:  Jie Li; Junjie Mai
Journal:  Tumour Biol       Date:  2014-08-14

Review 4.  Advances in understanding the pathogenesis of primary Sjögren's syndrome.

Authors:  Gaëtane Nocturne; Xavier Mariette
Journal:  Nat Rev Rheumatol       Date:  2013-07-16       Impact factor: 20.543

5.  Serum levels of the chemokine CXCL13, genetic variation in CXCL13 and its receptor CXCR5, and HIV-associated non-hodgkin B-cell lymphoma risk.

Authors:  Shehnaz K Hussain; Weiming Zhu; Shen-Chih Chang; Elizabeth Crabb Breen; Elena Vendrame; Larry Magpantay; Dan Widney; Daniel Conn; Mary Sehl; Lisa P Jacobson; Jay H Bream; Steven Wolinsky; Charles R Rinaldo; Richard F Ambinder; Roger Detels; Zuo-Feng Zhang; Otoniel Martínez-Maza
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-12-18       Impact factor: 4.254

6.  Blood methylomics in response to arsenic exposure in a low-exposed US population.

Authors:  Xin Liu; Yinan Zheng; Wei Zhang; Xiao Zhang; Donald M Lioyd-Jones; Andrea A Baccarelli; Hongyan Ning; Myriam Fornage; Ka He; Kiang Liu; Lifang Hou
Journal:  J Expo Sci Environ Epidemiol       Date:  2013-12-25       Impact factor: 5.563

7.  CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis.

Authors:  Bridget Charbonneau; Alice H Wang; Matthew J Maurer; Yan W Asmann; Clive S Zent; Brian K Link; Stephen M Ansell; George J Weiner; Nazan Ozsan; Andrew L Feldman; Thomas E Witzig; Julie M Cunningham; Ahmet Dogan; Thomas M Habermann; Susan L Slager; Anne J Novak; James R Cerhan
Journal:  Cancer Immunol Immunother       Date:  2013-06-28       Impact factor: 6.968

Review 8.  B cells in the pathogenesis of primary Sjögren syndrome.

Authors:  Gaëtane Nocturne; Xavier Mariette
Journal:  Nat Rev Rheumatol       Date:  2018-02-08       Impact factor: 20.543

9.  C-X-C chemokine receptor type 5 gene polymorphism affects gene expression in CD4+ T cells and is associated with increased risk of colorectal cancer.

Authors:  Junjie Xing; Xu Li; Jinke Sui; Guangwen Cao; Chuangang Fu
Journal:  Tumour Biol       Date:  2014-05-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.